Company: SMNR
Filing Date: 2025-03-25
Form Type: PRER14A
Source: 0001013762-25-002297
Chunk: 21

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-03-25
Form: PRER14A
Chunk 21
---
 liquidity and trading; •the lack of a market for our securities; •the use of proceeds not held in the trust account or available to us from interest income on the trust account balance; •the trust account not being subject to claims of third parties; or •our financial performance following our initial public offering. The forward -lookingstatements contained in this proxy statement are based on our current expectations and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward -lookingstatements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward -lookingstatements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” in this proxy statement and in our Annual Report on Form 10 -Kfor the year ended December 31, 2023 and in our other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward -lookingstatements. We undertake no obligation to update or revise any forward -lookingstatements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. 13 RISK FACTORS You should consider carefully all of the risks described in our Annual Report on Form 10 -Kfiled with the SEC on April 1, 2024 and in the other reports we file with the SEC before making a decision on how to vote your shares. Furthermore, if any of the following events occur, our business, financial condition and operating results may be materially adversely affected or we could face liquidation. In that event, the trading price of our securities could decline, and you could lose all or part of your investment. The risks and uncertainties described in the aforementioned filings and below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business, financial condition and operating results or result in our liquidation. There are no assurances that the extension will enable us to complete an initial business combination. Approving the extension involves a number of risks. Even if the extension is approved, the Company can provide no assurances that an initial business combination will be consummated prior